A 32-year-old woman from Mumbai with PCOS (Rotterdam criteria: irregular cycles, elevated androgens, polycystic ovaries on ultrasound) and BMI 28 kg/m² presents with secondary infertility of 2 years. Fasting glucose is 95 mg/dL; fasting insulin 18 mIU/L (HOMA-IR = 4.3, indicating insulin resistance). FSH and LH are normal. She was started on clomiphene citrate 100 mg daily for 5 days but failed to ovulate in two consecutive cycles. What is the most appropriate next step in management?

Explanation

## Clinical Scenario Analysis This patient has **PCOS with clomiphene resistance** (failure to ovulate at 100 mg daily × 2 cycles) and **documented insulin resistance** (HOMA-IR 4.3). The next step must address both the clomiphene resistance and the underlying insulin dysfunction. ## Management Algorithm for Clomiphene-Resistant PCOS ```mermaid flowchart TD A[PCOS + Clomiphene Failure]:::outcome --> B{Insulin Resistance Present?}:::decision B -->|Yes| C[Letrozole ± Metformin]:::action B -->|No| D[Letrozole alone]:::action C --> E[Ovulation rate 60-70%]:::outcome D --> F[Ovulation rate 50-60%]:::outcome E --> G{Ovulation achieved?}:::decision G -->|No| H[Escalate to Gonadotropins]:::action G -->|Yes| I[Timed intercourse/IUI]:::action ``` ## Why Letrozole + Metformin? **Key Point:** Letrozole is superior to clomiphene in PCOS-related anovulation, particularly in clomiphene-resistant cases. Combined with metformin in insulin-resistant PCOS, it addresses both ovulatory dysfunction and metabolic abnormality. ### Letrozole Advantages in PCOS 1. **Mechanism:** Aromatase inhibitor → ↓ estrogen → ↑ endogenous FSH (similar to clomiphene) BUT does not deplete estrogen receptors or have antiestrogenic effects on endometrium. 2. **Endometrial benefit:** Preserves endometrial thickness (clomiphene can thin endometrium in PCOS). 3. **Ovulation rates:** 60–70% in clomiphene-resistant PCOS vs. 40–50% with clomiphene. 4. **Pregnancy rates:** Higher in PCOS compared to clomiphene. 5. **Androgen suppression:** Mild additional benefit in hyperandrogenic PCOS. **High-Yield:** Standard letrozole dosing is **2.5 mg daily for 5 days from day 3 of cycle**. Monitoring is identical to clomiphene (ultrasound on day 10–12). ### Metformin Role - **Insulin sensitizer:** Improves insulin resistance (HOMA-IR reduction of 20–30%). - **Androgen reduction:** Lowers testosterone and improves ovulation rates in PCOS. - **Synergistic effect:** Letrozole + metformin shows superior ovulation rates vs. letrozole alone in insulin-resistant PCOS. - **Dosing:** 1500–2000 mg daily in divided doses; start low to minimize GI side effects. **Clinical Pearl:** Metformin should be continued throughout the ovulation induction cycle and into pregnancy (reduces PCOS-related miscarriage risk). ## Why Not the Other Options? | Option | Rationale for Rejection | |--------|------------------------| | Clomiphene 150 mg | Already failed at 100 mg × 2 cycles. Dose escalation beyond 150 mg has diminishing returns; patient is clomiphene-resistant, not clomiphene-underdosed. | | Gonadotropins immediately | Second-line agent, reserved for letrozole failure or when IVF planned. Requires daily injections, frequent monitoring, higher OHSS risk in PCOS. Letrozole is less invasive and more cost-effective. | | IVF directly | Premature escalation. Letrozole + metformin has not been exhausted; IVF is reserved for failed medical ovulation induction or male factor/tubal pathology. | ## Monitoring Letrozole + Metformin 1. **Transvaginal ultrasound:** Day 10–12 to assess dominant follicle (≥18 mm). 2. **LH surge detection:** Optional; timed intercourse when mature follicle identified. 3. **Serum progesterone:** Day 21 to confirm ovulation (>5 ng/mL). 4. **Metformin tolerability:** Monitor for GI side effects; counsel on gradual dose escalation. **Mnemonic:** **PCOS Clomiphene Failure → LETROZOLE** (Letrozole Effective Treatment for Resistant Ovulation in PCOS; Zygote Enhancement; Ovulation Restoration; Luteal support Enhancement).